- Conditions
- HIV Infections
- Interventions
- APRETUDE, Cabotegravir OLI
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 287 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hiv
- Interventions
- Cabotegravir Injection [Apretude]
- Drug
- Lead sponsor
- Midway Specialty Care Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Temple Terrace, Florida • West Palm Beach, Florida
- Conditions
- HIV, Substance Use Disorder (SUD), Injection Drug Use
- Interventions
- APRETUDE (cabotegravir)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Prevention
- Interventions
- LA-CAB, TDF/FTC
- Drug
- Lead sponsor
- Orlando Immunology Center
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- HIV/AIDS
- Interventions
- Cabotegravir Injection
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- HIV, STI
- Interventions
- PrEP discontinuation intervention, Offering of on-demand oral PrEP, Offering of STI PEP, Injectable PrEP
- Behavioral · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HIV Infections
- Interventions
- APRETUDE, Cabotegravir tablet
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 295 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 22
- States / cities
- Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 13 more
- Conditions
- HIV Infections
- Interventions
- Cabotegravir Injection [Apretude]
- Drug
- Lead sponsor
- Kelley-Ross & Associates, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Pre-Exposure Prophylaxis (PrEP), Breast Feeding
- Interventions
- Cabotegravir Injection [Apretude]
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV, Prophylaxis, Injectable
- Interventions
- Cabotegravir Injectable Suspension (CAB LA)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland